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Abstract
Human papilloma viruses (HPV) are strong human carcinogens, in fact today they are considered as the second most frequent carcino-
gen. In the middle of the 1970s the hypothesis that cervical cancer may arise from viruses was established and in the 1990s the relation-
ship between HPV and cervical neoplasia was conﬁrmed. HPV infections are the most common sexually transmitted infections. Speciﬁc
subtypes of human papilomaviruses are now considered as the etiological agents in nearly all cases of cervical cancer and cervical epithe-
lial neoplasia. Approximately 470 000 new cases and 230 000 deaths of cervical cancer occur each year, with the majority taking place
in developing countries. Cervical cancer remains among the three leading causes of cancer deaths among women below the age of 45.
Human papilomaviruses are classiﬁed into two groups: high-risk (oncogenic) types and low risk types. HPV types 16, 18, 45 and 31 are
considered to be the most important oncogenic types. Subtypes 16 and 18 are the causative agents of more than 50% of cervical pre-
cancerous lesions, and more than 70% of cervical cancer cases. High risk subtypes are also implicated with anal, perianal and oropharyn-
geal carcinomas. Recently, the prophylactic bivalent HPV 16/18 and the quadrivalent HPV 6/11/16/18/ vaccines have been approved. The
development of prophylactic vaccines against human papilomavirus has been hailed as one of the most signiﬁcant advances of recent
years and it is expected to reduce dramatically the mortality of human papilomavirus associated cancers, but has also given rise to some
of the most intense scientiﬁc debates.
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Introduction
Approximately 470 000 new cases of cervical cancer are
diagnosed annually and approximately 230 000 women
worldwide die from the disease each year. The majority (c.
80%) of these cases and deaths occur in developing coun-
tries. In approximately 60% of all countries, mainly in less
developed regions, cervical cancer dominates as the ﬁrst or
second most frequent malignancy, often afﬂicting relatively
young females. Although cervical cancer is considered to be
a preventable disease, it remains one of the three leading
cancers among women below the age of 45 years in up to
90% of all countries, including developed and less developed
regions [1].
In the 1990s, molecular biology technology and epidemio-
logical studies established the relationship between some
speciﬁc subtypes of human papilloma virus (HPV) persistent
infections and cervical cancer. Historically, in the middle of
the 1970s, the hypothesis that cervical cancer may arise from
infections with the virus found in condylomata acuminate
was established [2,3]. In 1976, it was reported that koilocytic
cells found in cervical smears of patients with dysplastic
lesions characterize the pathological change in HPV infection
[4]. Today, it is well known that infection with high-risk HPV
subtypes can cause cervical cancer. More than 95% of cervi-
cal cancer biopsies contain HPV genomes; however, this
does not necessarily imply that all of these tumours are
caused by these infections [5].
HPV and Cervical Cancer
HPV are now considered to be the aetiological agents in
almost all cases of invasive cervical cancer and cervical intra-
epithelial neoplasia (CIN). Indeed, based on epidemiological,
clinical and laboratory-based evidence, HPV has been identi-
ﬁed as the ‘necessary cause’ of cervical cancer (i.e. cervical
cancer does not and will not develop in the absence of the
persistent presence of HPV DNA) [6]. This association is
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stronger than that between cigarette smoking and lung can-
cer; however, the development of cervical cancer subsequent
to HPV infection is not inevitable. It has been estimated that,
for every one million women who are infected, only 10% or
100 000 will develop pre-cancerous cervical cell changes
(cervical dysplasia). Among these, approximately 8% (8000)
will develop early cancer conﬁned to the outer layers of the
cervical cells (carcinoma in situ) and approximately 1600 of
these women will go on to develop invasive cervical cancer.
Moreover, mortality rates are signiﬁcantly lower than the
incidence of cervical cancer (Fig. 1). It is estimated that,
worldwide, the ratio of mortality to incidence is 55%.
The Virus
HPV are non-enveloped viruses composed of a double-
stranded, closed circular DNA genome. HPV is genetically
stable, unlike other viruses such as inﬂuenza. Genetic studies
indicate that the biology of HPV has remained essentially the
same for over 200 000 years [7].
HPV infections are the most common sexually transmit-
ted infections. Both men and women can be affected; they
can be asymptomatic carriers, transmitters, or can be
infected with HPV. HPV transmission may occur even with
skin-to-skin genital contact. Common risk factors include
the number of sexual partners, an early age at ﬁrst inter-
course, and any previous sexually transmitted disease. The
parameters of sexual behaviour, in general, reﬂect the risk
of HPV infection. Studies have shown that the risk of a
given woman for cervical cancer can be predicted by her
own sexual behaviour or by her husband’s/partner’s sexual
behaviour. A woman’s risk of developing cervical cancer has
been shown to be related to the presence of HPV in the
penis or the urethra of her husband/sexual partner. It is
estimated that a women’s life-time risk of acquiring one or
more genital HPV infections is at least 75%. Male circumci-
sion protects males from HPV infection and their wives or
sexual partners from developing cervical cancer. Additional
proposed risk factors for developing cervical cancer (which
have been inconsistently documented in related studies) are
the prolonged use of oral contraceptives, high parity, and
cigarette smoking. Possible factors include dietary habits, in
particular diets poor in fruits and vegetables, as well as co-
infection with other sexually transmitted pathogens, such as
Chlamydia trachomatis and herpes simplex virus type 2 [8],
and co-infection with more than one HPV type [9]. More-
over, HIV infection and other immunosuppressive situations
are related to an increased risk of disease persistence and
progression, indicating a theoretical background for long-
term viral persistence in a latent form that eventually
evolves when immune guarding allows for it.
Viral Oncogenic Potential
Over 200 papilloma virus types have been described,
approximately 100 of which infect humans and are there-
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FIG. 1. Natural history of oncogenic human
papilloma virus (HPV) infection.
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fore classiﬁed as HPV. There are approximately 40–60
types of HPV speciﬁcally infecting the genital area and these
are classiﬁed into two groups: high-risk (or oncogenic)
types and low-risk types [10]. The most important onco-
genic types have now been fully characterized. Munoz et al.
[11], in a pooled analysis of all cancer types, found HPV
types 16, 18, 45 and 31 to be the most important of the
ongogenic types. The most recent designations of the Inter-
national Agency for Research in Cancer, along with their
relative impact on the causes of cervical cancer, are
depicted in Fig. 2. Globally, types 16 and 18 together are
the causative agent of more than 50% of cervical pre-can-
cerous lesions (high-grade dysplasias), more than 70% of all
cases of cervical squamous cell carcinoma and adenocarci-
noma, and 25% of low-grade cervical lesions. Squamous cell
carcinoma is the typical lesion, whereas adenocarcinoma
represents 10–15% of cervical cancers, particularly in the
developed world.
HPV and Other Cancers
Because HPV expresses a predilection for transitional zones,
it is also implicated in other cancers. High-risk HPV types
are implicated in penile, vulvar, vaginal, anal and oropharyn-
geal carcinomas. Speciﬁcally, approximately 50% of vulvar
squamous cell carcinomas [12] and 30–50% of penile carci-
nomas [13,14] are HPV-related. In general, HPV-positive
vulva and penile neoplasms appear to have a better progno-
sis compared to the HPV-negative tumours [14]. By contrast
to penile and vulvar cancers, carcinomas of the vagina are
HPV-positive in 60–90% of cases [12]. The same appears to
be true for anal and perianal cancers. Furthermore, it is
now well established that 20–75% of oropharyngeal cancers
are HPV-positive. HPV-related oropharyngeal carcinoma is
associated with better clinical outcome as compared with
the non-HPV-related oropharyngeal cancer. In cervical can-
cer, the number of high-risk types is restricted to 12–15
types.
HPV Epidemiology
Worldwide, HPV 16 is the most common type implicated in
cervical cancer, with a prevalence ranging from 47.7% in sub-
Saharan Africa to 69.7% in Europe/North America [15]. HPV
18 is the second most common cause of cervical cancer,
with a prevalence ranging from 12.6% in Central/South
America to 25.7% in Southern Asia [15]. HPV 18 is more
frequently the cause of cervical adenocarcinoma than HPV-
16. The two most common low-risk HPVs, genotypes 6 and
11, cause genital warts or condylomata accuminata and low-
grade intraepithelial lesions. HPV 6 and 11 are found in over
90% of anogenital warts [16] and these are not associated
with oncogenesis in the cervix [11]. They also cause recur-
rent respiratory papillomatosis.
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FIG. 2. Human papilloma virus (HPV) types
characterized as oncogenic and their relative
contribution to cervical cancer development.
Values are shown as percentages, with data
estimates derived from Arbyn and Dillner
[27].
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The prevalence in low-risk/general population females var-
ies with age as well as geographically; a 15% median preva-
lence of oncogenic types in all females has been reported
[17], although the prevalence in females aged >30 years is
9.2%. A peak is observed at or approaching age 25 years,
with a subsequent decrease in prevalence and a possible sec-
ond peak at or approaching age 55 years [18].
Pathophysiology of Carcinogenesis
Persistent infection with one or more high-risk subtypes
over time leads to the development and progression of CIN
disease. The progressive development of cellular changes
starts with infection of the basal cell layers of the epithelium.
The entire process generally takes place over a period of
10–40 years, although it may take place in only 1–2 years in
some cases. CIN I changes can arise within 3 months of
infection, whereas CIN II changes arise within 6 months, and
CIN III changes within 1–2 years. Whether pathogen viru-
lence factors or inherent host immune factors are decisive in
the speed of the oncogenic process remains to be clariﬁed.
Abnormal infected cells and CIN I can also be termed low-
grade squamous intraepithelial lesions, whereas CIN II and
CIN III can also be termed high-grade squamous intraepithe-
lial lesions. The development of CIN I is not necessarily a
precursor to cancer, and can be observed even with non-
oncogenic type HPV infection. Even CIN II changes can
regress naturally. A substantial fraction of women with high-
risk HPV DNA who are cytomorphologically normal will
develop CIN II or CIN III within 4 years. By contrast,
women negative for high-risk HPV DNA, even though cyto-
logically abnormal (with atypical squamous cells of undeter-
mined signiﬁcance, or borderline or mild dysplasia) are
unlikely to develop CIN II/III during a follow-up period of
2 years, and their cytology is likely to return to normal [6].
The E6 and E7 proteins of the oncogenic HPV are gener-
ally recognized as the dominant oncoproteins [19]. The
major mechanisms through which HPV contributes to carci-
nogenesis include the activity of these two viral oncopro-
teins, which interfere with the critical cell cycle tumour
suppressive proteins, p53 (E6) and retinoblastoma (Rb) pro-
tein (E7). Moreover, E6 and E7 oncoproteins are also associ-
ated with viral and host DNA methylation changes, many of
which also occur in cancer types that are not related to
HPV infection. The E6 and E7 interactions with the cellular
proteins and with DNA methylation changes are associated
with alterations in key cellular pathways that regulate geno-
mic integrity, cell adhesion, the immune response, apoptosis
and cell cycle control [20].
Vaccines for Prophylaxis
Papilloma viruses possess a major capsid protein called L1
that has the ability to self-assemble in viral-like particles and
to be expressed in eukaryotic cells [21]. Human papilloma
viruses are localized in the epithelium and thus have minimal
contact with the host immune system and, in general, the
immune response can be low-grade and transient.
With the development of the HPV viral-like particles,
however, the ﬁrst generation of prophylactic vaccines was
feasible. Clinical trials of prophylactic bivalent HPV 16/18 and
quadrivalent HPV 6/11/16/18 vaccines demonstrated that the
vaccines were well tolerated, without serious adverse events,
and were highly effective in preventing HPV infection. In June
2006, a quadrivalent vaccine was approved by the US Food
and Drug Administration for the prevention of HPV 6/11/16/
18-associated cervical cancer, adenocarcinoma in situ, cervical
intraepithelial neoplasia, vulvar intraepithelial neoplasia, vagi-
nal intraepithelial neoplasia and genital warts in women.
A bivalent vaccine that protects against HPV 16 and 18 has
also been approved in Europe.
The development of prophylactic vaccines for HPV onco-
genic types has been hailed as one of the most signiﬁcant sci-
entiﬁc advances of recent years, but has also given rise to
some of the most intense scientiﬁc debates regarding the
implementation, planning and cost-effectiveness of vaccina-
tion. Compulsory vaccination is still not implemented in cer-
tain countries of the Western world, and religious, ethical
and political issues have been raised, understandably, because
sexual behaviour and related policies are implicated [22].
One important issue regarding evaluation of prophylactic
vaccine efﬁcacy is that the major endpoint (i.e. a reduction in
incidence of cervical cancer) can only be evaluated after dec-
ades of implementation of vaccination; thus, mathematical
models (with all the resulting statistical inconsistencies and
differences in modelling) have been incorporated, aiming to
demonstrate vaccine effectiveness [23–25]. Long-term efﬁ-
cacy has been recently re-conﬁrmed, extending to a 5-year
period. Questions arise regarding vaccination of older
females, with some studies supporting the idea that partial
protection may be offered to a subset of HPV-negative
females [26]. Moreover, vaccination of males has been dis-
cussed as a potential inducer of herd immunity by minimizing
the pool by which females become infected; mathematical
models, however, have shown that the impact of such an
extended vaccination programme would be borderline, and
deﬁnitely not cost-effective. Further questions regard the
potential impact on HPV ecology (i.e. whether mass vaccina-
tion will lead to a higher incidence of other oncogenic HPV
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types). Another issue that has not been evaluated is that of
the impact of mass vaccination on the overall incidence of
other cancers, apart from cervical cancer, that are aetiologi-
cally related to HPV. Finally, a consistently raised issue is that
of screening, which subsequently inﬂuences the planning of
vaccination policies and impacts modelling. An aggressive
screening approach may, for example, reveal a small minority
of young patients with rapidly developing disease and would
simultaneously identify a signiﬁcant number of females with
lesions that would regress naturally.
Conclusions
In summary, HPV today is considered to be the second most
frequent human carcinogen, accounting for 5% of human can-
cers, 10% of cancers in women, and 15% of cancers in
women in developing countries. The percentage of cases
linked to HPV 16 and 18 subtypes is potentially preventable.
The established safety and efﬁcacy of both HPV vaccines
supports their widespread administration, which is expected
to reduce dramatically the incidence and mortality of HPV-
associated cancers.
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